MEI Pharma stockholders elect directors and approve say-on-pay at 2023 annual meeting

Proposal 3. – Advisory Vote on Frequency of Advisory Vote on Executive Compensation. Proposal 3 was to approve, on an advisory basis, on the frequency of the approved, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement. The proposal was approved. 1 Year 2 Years 3 Years Abstain Broker Non-Votes 2,534,092 1,870 102,716 29,535 1,745,025

Proposal 2. – Advisory Vote on Executive Compensation. Proposal 2 was to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement. The proposal was approved. For Against Abstain Broker Non-Votes 2,510,335 149,459 8,419 1,745,025

Proposal 1. – Election of Director. The following individuals, who were named as nominees in the Company’s definitive proxy statement relating to the Annual Meeting, were elected by the Company’s stockholders by a plurality of votes cast to serve a three-year term on the Company’s Board of Directors which will expire at the Company’s annual meeting of stockholders for fiscal year 2027. Information on the vote relating to the director standing for election is set forth below: Nominee For Withheld Broker Non-Votes Mr. James Flynn 2,643,853 24,360 1,745,025 Mr. Taheer Datoo 2,230,727 435,794 1,746,717 Mr. Steven Wood 2,644,765 23,448 1,745,025

Proposal 4. – Ratification of Appointment of BDO USA, P.C. Proposal 4 was to ratify the appointment of BDO USA, P.C., an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending June 30, 2024. The proposal was approved. For Against Abstain 4,366,180 24,327 22,731